New Metabolic Biomarkers Open Door to Earlier Diagnosis, More Precise and Individualized Treatment of Children at Risk for Autism
168023
post-template-default,single,single-post,postid-168023,single-format-standard,bridge-core-1.0.5,tribe-no-js,tribe-bar-is-disabled,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.1,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-6.0.2,vc_responsive
 

New Metabolic Biomarkers Open Door to Earlier Diagnosis, More Precise and Individualized Treatment of Children at Risk for Autism

NeuroPoint-logo

New Metabolic Biomarkers Open Door to Earlier Diagnosis, More Precise and Individualized Treatment of Children at Risk for Autism

NeuroPointDX presents further data from the Children’s Autism Metabolome Project at INSAR 2019

MADISON, WI (May 6, 2019): Continued analysis of samples from the Children’s Autism Metabolome Project (CAMP), the most comprehensive clinical study of metabolism in children who has autism spectrum disorder (ASD) conducted to date, has identified three new areas of metabolism that affect the biology of children with ASD. These include biomarkers indicating that altered neurotransmission, energy metabolism, and purine metabolism may be associated with metabotypes (metabolic subtypes) of ASD. Stratifying ASD based on metabotypes both offers an opportunity for earlier identification of children at risk for an ASD diagnosis, as well as a potential strategy for more precise and individualized treatment of some affected children. The addition of these metabotypes to the previously published branch-chain amino acid dysregulation subtypes in the biomarker test panel under development by NeuroPointDX can now help identify approximately 41% of ASD-affected children as early as 18 months of age.

 

READ FULL STORY